[1] SIMKO V, GINTER E. Understanding cholesterol: high is bad but too low may also be risky—is low cholesterol associated with cancer? [J]. Bratislavske Lekarske Listy , 2014, 115(2):59-65. [2] CRUZ P M R, MO H, MCCONATHY W J, et al. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics[J]. Frontiers in Pharmacology , 2013, 4: 119. [3] KANUNGO S, SOARES N, HE M, et al. Sterol metabolism disorders and neurodevelopment-an update[J]. Developmental Disabilities Research Reviews , 2013, 17(3):197-210. [4] KIM J Y, PARK J H, JEONG S W, et al. High levels of remnant lipoprotein cholesterol is a risk factor for large artery atherosclerotic stroke[J]. Journal of Clinical Neurology , 2011, 7(4):203-209. [5] SEO Y H, LEE C S, YUK H B, et al. Hypercholesterolemia and in-vivo coronary plaque composition in patients with coronary artery disease: a virtual histology-intravascular ultrasound study[J]. Korean Circulation Journal , 2013, 43(1):23-28. [6] DAVIS JR H R, ZHU L J, HOOS L M, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis[J]. The Journal of Biological Chemistry , 2004, 279(32):33586-33592. [7] TANG W, MA Y, JIA L, et al. Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice[J]. Arteriosclerosis Thrombosis & Vascular Biology , 2008, 28(3):448-454. [8] DEUSHI M, NOMURA M, KAWAKAMI A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome[J]. FEBS Letters , 2007, 581(29):5664-5670. [9] HUGHES E A, TRACEY I, SINGHAL S, et al. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease[J]. Medical Hypotheses , 2006, 67(6):1463-1464. [10] LABONTÉ E D, CAMAROTA L M, ROJAS J C, et al. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1 - / - mice[J]. American Journal of Physiology Gastrointestinal & Liver Physiology , 2008, 295(4):G776-783. [11] ASSY N, GROZOVSKI M, BERSUDSKY I, et al. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease[J]. World Journal of Gastroenterology , 2006, 12(27):4369-4376. [12] SPIRLANDELI A L, DENINICE R, JORDAO A A. Plasma malondialdehyde as biomarker of lipid peroxidation: effects of acute exercise[J]. International Journal of Sports Medicine , 2014, 35(1):14-18. [13] RAGHAVAN S, SUBRAMANIYAM G, SHANMUGAM N. Proinflammatory effects of malondialdehyde in lymphocytes[J]. Journal of Leukocyte Biology , 2012, 92(5):1055-1067 [14] POLI G, SCHAUR R J, SIEMS W G, et al. 4-Hydroxynonenal: A membrane lipid oxidation product of medicinal interest[J]. Medicinal Research Reviews , 2008, 28(4):569-631. [15] JAKOBSEN J E, JOHANSEN M G, SCHMIDT M, et al. Generation of minipigs with targeted transgene insertion by recombinase-mediated cassette exchange (RMCE) and somatic cell nuclear transfer (SCNT)[J]. Transgenic Research , 2013, 22(4):709-723. [16] DE CECCO M, SPINACI M, ZANNONI A, et al. Coupling sperm mediated gene transfer and sperm sorting techniques: a new perspective for swine transgenesis[J]. Theriogenology , 2010, 74(5):856-862. [17] SCOTT P A, FERNANDEZ DE CASTRO J P, KAPLAN H J, et al. A Pro23His mutation alters prenatal rod photoreceptor morphology in a transgenic swine model of retinitis pigmentosa[J]. Investigative Ophthalmology & Visual Science , 2014, 55(4):2452-2459. [18] WOLF E, BRAUN-REICHHART C, STRECKEL E, et al. Genetically engineered pig models for diabetes research[J]. Transgenic Research , 2014, 23(1):27-38. |